NCT06675175 - A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 9, 2024

Primary Completion Date

October 27, 2025

Study Completion Date

October 27, 2025

Conditions

Chronic Kidney DiseaseAtherosclerotic Cardiovascular Disease

Interventions

DRUG

AZD4144

Oral solution of AZD4144 will be given to randomised participants as per the arm they have been assigned.

OTHER

Placebo

Placebo will be given orally to randomized participants as per the arm they are assigned.

Trial Locations (15)

1527

Research Site, Sofia

2143

Research Site, Kistarcsa

3200

Research Site, Gyöngyös

5800

Research Site, Pleven

10455

Research Site, The Bronx

11658

Research Site, Bucharest

32117

Research Site, Daytona Beach

32127

Research Site, Port Orange

32216

Research Site, Jacksonville

33125

Research Site, Miami

33603

Research Site, Tampa

48334

Research Site, Farmington Hills

75092

Research Site, Sherman

91203

Research Site, Glendale

400006

Research Site, Cluj-Napoca